Aggressive B cell lymphomas—highlights from ASH 2022
- 02.08.2023
- short review
Erschienen in:
- Verfasst von
- Michael Panny
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 3/2023
Summary
The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of diffuse large B cell lymphoma (DLBCL) as a one shot cancer. CD-19-targeted CART cell therapy, CD79b-targeted antibody drug conjugate polatuzumab vedotin, and CD 19 antibody tafasitamab in combination with lenalidomide are approved in relapsed/refractory (r/r) disease. Recently the bispecific CD20/CD3 antibody glofitamab received approval for third-line therapy and approval for other CD20/CD3 bispecific antibodies is expected soon. This short review is a personal selection of the clinically most relevant abstracts besides CART therapy regarding aggressive B cell lymphomas presented at the 2022 ASH meeting in San Diego.
Anzeige
- Titel
- Aggressive B cell lymphomas—highlights from ASH 2022
- Verfasst von
-
Michael Panny
- Publikationsdatum
- 02.08.2023
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-023-00908-y
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.